Novare Announces Research Agreement with Lawson Health Research Institute
May 21 2015 - 08:00AM
Business Wire
- The agreement includes the creation
of an incubator focused on potential treatments for major diseases
such as breast cancer and lung fibrosis using the modulation of
RHAMM.
- The incubator will be led by Dr. Eva
Turley, a globally recognized leader in RHAMM research and a
Professor in the Department of Oncology at Western University, who
also serves as Chief Scientist for Novare.
Novare Pharmaceuticals, which is developing therapeutic products
that modulate the Receptor for Hyaluronan-Mediated Motility
(RHAMM), is pleased to announce a research and licensing agreement
with Lawson Health Research Institute that includes the creation of
an incubator focused on potential treatments for major diseases,
including arthritis, breast cancer, and lung fibrosis.
The Novare research incubator in the city of London, Ontario,
Canada is being led by Dr. Eva Turley, Chief Scientist at Novare
and a global leader in RHAMM research as a Professor in the
Department of Oncology, Western University, and Scientist in the
London Regional Cancer Program, London Health Sciences Centre. She
is joined by Dr. Leonard Luyt, who is an Assistant Professor in the
same university oncology department as well as a Principal
Investigator in the cancer program, and who is assisting with the
development of proprietary peptides being used in Novare’s drug
development programs.
“Our agreement with Lawson allows us to bring together the top
minds in the field of RHAMM, providing us with a unique opportunity
to go after major disease states,” said Michael Delmage, Chief
Executive Officer of Novare. “Combining Novare’s business acumen in
drug development, regulatory approval and quality assurance with
the translational science expertise, infrastructure and facilities
at Lawson will help to ensure that this research focuses on finding
benefits for real patients fighting real diseases.”
Novare is investigating the modulation of RHAMM, a cellular
protein that helps to regulate cell movement and stem cell
differentiation. Therapeutic products that control RHAMM aim to
safely and selectively stimulate cell differentiation as well as
reduce destructive inflammation and scarring inherent in diseases
such as lung fibrosis and arthritis. Other potential applications
include breast cancer, scarless healing for burns and post-surgical
wounds, and the regeneration of breast tissue after a
mastectomy.
“The Lawson and Novare partnership serves as an inspiring and
much-needed model for the development of early-stage technologies
from academic health research organizations,” said Dr. Turley. “The
partnership with Novare helps Lawson fulfill its mandate to
translate healthcare discoveries from the lab to the patient.”
Lawson Health Research Institute is the research institution of
London Health Sciences Centre and St. Joseph’s Health Care London.
The group of more than 1,600 investigators, technicians and support
staff collaborate to advance scientific knowledge related to
healthcare topics such as aging, cancer and neurological
disorders.
“Novare’s funding is critical in the current environment of
reduced traditional funding sources for validation of early-stage
research and discovery,” said Kirk Brown, Manager for Business
Development at Lawson. “The partnership with Novare has also
allowed us to create new jobs for our community, bolstering our
efforts to create economic, as well as medical, benefits from our
research.”
About Novare Pharmaceuticals
Novare Pharmaceuticals develops therapeutic products that
modulate RHAMM, a natural protein that alters migratory cell
behavior and promotes cell differentiation. Novare is at the
forefront of finding treatments for a wide variety of inflammatory
conditions, including Bronchopulmonary Dysplasia (BPD) in premature
infants and arthritis, to fibrotic diseases, such as Idiopathic
Pulmonary Fibrosis (IPF). RHAMM modulation can also play a role in
controlling breast cancer and additionally can provide a means of
tissue engineering that promotes the regeneration of breast tissue
after a mastectomy. The company is a subsidiary of Allied Minds
(LSE:ALM), an innovative U.S. science and technology development
and commercialization company based in Boston. More
information about the company can be found on its
website, www.novarepharma.com
About Lawson Research Institute
The Lawson Health Research Institute is located in London,
Ontario, Canada and is the research institute of London Health
Sciences Centre and St. Joseph's Health Care London. As one of
the largest hospital-based research institutes in Canada, Lawson is
committed to furthering scientific knowledge to advance health care
around the world. Further information on Lawson can be found at
www.lawsonresearch.com
About Allied Minds
Allied Minds (LSE:ALM) is an innovative U.S. science and
technology development and commercialization company. Operating
since 2006, Allied Minds forms, funds, manages and builds products
and businesses based on innovative technologies developed at
leading U.S. universities and federal research institutions. Allied
Minds serves as a diversified holding company that supports its
businesses and product development with capital, central management
and shared services. More information about the Boston-based
company can be found at www.alliedminds.com
Allied Minds Forward-Looking Statement
This press release contains statements that are or may be
forward-looking statements, including statements that relate to the
company’s future prospects, developments and strategies. The
forward-looking statements are based on current expectations and
are subject to known and unknown risks and uncertainties that could
cause actual results, performance and achievements to differ
materially from current expectations, including, but not limited
to, those risk and uncertainties described in the risk factors
included in the company’s regulatory filings. These forward-looking
statements are based on assumptions regarding the present and
future business strategies of the company and the environment in
which it will operate in the future. Each forward-looking statement
speaks only as at the date of this press release. Except as
required by law, regulatory requirement, the Prospectus Rules, the
Listing Rules and the Disclosure and Transparency Rules, neither
the company nor any other party intends to update or revise these
forward-looking statements, whether as a result of new information,
future events or otherwise.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150521005373/en/
Media:ArcPoint Strategic CommunicationsChristine Dunn,
617-484-1660 x101cdunn@arcpointstrategy.com
Allied Minds (LSE:ALM)
Historical Stock Chart
From Feb 2024 to Mar 2024
Allied Minds (LSE:ALM)
Historical Stock Chart
From Mar 2023 to Mar 2024